Targeting glucocorticoid-induced CD20 activation in preclinical models of B-ALL
Authors:
- Jérémy BigotJBJérémy Bigot
- Mathieu BouttierMBMathieu Bouttier
- Vincent FregonaVFVincent Fregona
- Clémence RouzierCRClémence Rouzier
- Manon BayetMBManon Bayet
- Sylvie HebrardSHSylvie Hebrard
- Naïs PradeNPNaïs Prade
- Stéphanie LagardeSLStéphanie Lagarde
- Christine DidierCDChristine Didier
- Laetitia LargeaudLLLaetitia Largeaud
- François VergezFVFrançois Vergez
- Anne Quillet-MaryAQAnne Quillet-Mary
Preprint
Abstract
Pediatric B-cell acute lymphoblastic leukemia (B-ALL) is effectively controlled with contemporary multi-agent chemotherapy, resulting to 5-year survival rates above 90%. However, relapse occurs in 15-20% of patients due to minimal residual disease (MRD), characterized by the presence of persisting and resistant leukemic cells, and associated with a poor clinical outcome. Despite its prognostic relevance, the molecular features driving MRD are poorly characterized. In this study, we developed patient-derived xenograft (PDX) models from matched diagnosis and relapse B-ALL samples combined to chemotherapy to mimic MRD in vivo . Drug-tolerant leukemic cells were profiled using single-cell RNA sequencing and we identified a transcriptionally distinct MRD-like population enriched for cell-quiescence, inflammatory stress, and B-cell receptor pathway signatures. Strikingly, the B-lymphocyte surface antigen CD20, encoding by MS4A1 gene, emerged as a consistent upregulated marker in MRD cells from PDXs and patients with diverse oncogenic subtypes. We further demonstrated that CD20 expression is induced by glucocorticoid exposure, creating a therapeutic opportunity where anti-CD20 monoclonal antibodies selectively eradicated MRD cells in vivo . Our data highlight CD20 not only as a biomarker but as an actionable vulnerability in B-ALL MRD, supporting clinical evaluation of anti-CD20 immunotherapy during induction treatment to kill drug-resistant cells and reduce relapse risk.Keywords
This publication has 48 references indexed in Scilit:
- CD72 is a pan‐tumor antigen associated to pediatric acute leukemiaCytometry Part A, 2023
- Clinicopathological impact of CD20 expression in childhood B cell precursor acute lymphoblastic leukemia (BCP-ALL)Comparative Clinical Pathology, 2017
- Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibitionLeukemia, 2016
- Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonistsNature, 2015
- Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic LeukemiaCancer Cell, 2015
- Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemiaBlood Cancer Journal, 2014
- Full-length RNA-seq from single cells using Smart-seq2Nature Protocols, 2014
- Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic LeukemiaCancer Cell, 2012
- Cancer stem cell definitions and terminology: the devil is in the detailsNature Reviews Cancer, 2012
- Hydrogen peroxide as second messenger in lymphocyte activationNature Immunology, 2002